Exscientia plc (NASDAQ:EXAI) Short Interest Up 15.7% in August

Exscientia plc (NASDAQ:EXAI) saw a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 3,690,000 shares, an increase of 15.7% from the July 31st total of 3,190,000 shares. Based on an average trading volume of 593,200 shares, the days-to-cover ratio is presently 6.2 days. Approximately 3.5% of the company’s stock are sold short.

Exscientia Stock Down 1.8 %

Exscientia stock traded down $0.10 during trading hours on Monday, reaching $5.56. The stock had a trading volume of 752,700 shares, compared to its average volume of 637,763. Exscientia has a 52 week low of $3.80 and a 52 week high of $7.91. The company has a market cap of $672.13 million, a price-to-earnings ratio of -4.24 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.93 and a quick ratio of 5.93. The business’s 50 day moving average price is $5.33 and its 200-day moving average price is $5.35.

Exscientia (NASDAQ:EXAI) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.05). The firm had revenue of $5.60 million for the quarter. Exscientia had a negative return on equity of 37.56% and a negative net margin of 620.99%. Sell-side analysts anticipate that Exscientia will post -1.25 EPS for the current year.

Wall Street Analysts Forecast Growth

EXAI has been the subject of several research reports. TD Cowen reaffirmed a “hold” rating on shares of Exscientia in a research report on Friday, August 9th. Barclays reaffirmed an “equal weight” rating and set a $5.00 target price on shares of Exscientia in a research report on Tuesday, August 13th.

Hedge Funds Weigh In On Exscientia

Large investors have recently made changes to their positions in the business. Novo Holdings A S acquired a new stake in Exscientia in the second quarter worth about $66,742,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Exscientia in the 2nd quarter valued at approximately $256,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Exscientia in the 2nd quarter worth approximately $54,000. Federated Hermes Inc. acquired a new stake in Exscientia in the 2nd quarter worth approximately $115,000. Finally, Bank of New York Mellon Corp grew its position in Exscientia by 108.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock worth $1,981,000 after purchasing an additional 202,377 shares during the last quarter. 41.58% of the stock is owned by institutional investors and hedge funds.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.